Health Discovery (HDVY) 10-K 30 Mar 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 30, 2016	Jun. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	HEALTH DISCOVERY CORP
Entity Central Index Key	1,141,788
Trading Symbol	hdvy
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Well-Known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding		268,718,989
Entity Public Float			$ 5,294,380
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Amendment Flag	false
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current Assets
Cash	$ 417,208	$ 7,642
Accounts Receivable		1,969
Investment in Available For Sale Securities (Note J)	141,978	362,373
Total Current Assets	559,186	371,984
Equipment, Less Accumulated Depreciation of $60,690 and $59,765 as of December 31, 2015 and 2014, respectively	195	1,120
Other Assets
Patents, Less Accumulated Amortization of $3,044,728 and $2,782,009 as of December 31, 2015 and 2014, respectively	941,066	1,203,785
Total Assets	1,500,447	1,576,889
Current Liabilities
Accounts Payable - Trade	37,633	239,910
Dividends Payable	206,637	373,346
Deferred Revenue	43,388	43,388
Common Stock Warrants Liability	339,268
Total Current Liabilities	626,926	656,644
Long Term Liabilities
Deferred Revenue	104,853	148,240
Total Liabilities	731,779	804,884
Stockholders' Equity
Common Stock, No Par Value, 300,000,000 Shares Authorized; 268,718,989 Shares Issued and Outstanding December 31, 2015; 261,384,810 Shares Issued and Outstanding December 31, 2014	27,410,930	27,055,938
Accumulated Deficit	(27,202,994)	(26,615,933)
Total Stockholders' Equity	768,668	772,005
Total Liabilities and Stockholders' Equity	1,500,447	1,576,889
Series C Preferred Stock Convertible
Stockholders' Equity
Series C Preferred Stock, Convertible, 30,000,000 Shares Authorized; 30,000,000 Issued and Outstanding December 31, 2015; 6,640,000 Issued and Outstanding December 31, 2014	$ 560,732	$ 332,000

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Accumulated depreciation on equipment (in dollars)	$ 60,690	$ 59,765
Accumulated amortization on patents (in dollars)	$ 3,044,728	$ 2,782,009
Common stock, no par value (in dollars per share)	$ 0	$ 0
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	268,718,989	261,384,810
Common stock, shares outstanding	268,718,989	261,384,810
Series C Preferred Stock Convertible
Preferred stock, shares authorized	30,000,000	30,000,000
Preferred stock, shares issued	30,000,000	6,640,000
Preferred stock, shares outstanding	30,000,000	6,640,000

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Revenues:
Licensing & Development	$ 44,601	$ 1,032,127
Operating Expenses:
Amortization	262,719	262,719
Professional and Consulting Fees	160,121	161,600
Legal Fees	40,357	58,950
Research & Development Fees	40,813	99,200
Compensation	192,701	249,475
Other General and Administrative Expenses	148,538	161,735
Total Operating Expenses	845,249	993,679
(Loss) Income From Operations	(800,648)	38,448
Other Income (Expense)
Unrealized Loss on Available for Sale Securities (Note J)	(123,161)	(199,894)
Realized Gain on Available for Sale Securities (Note J)	232,937	338,087
Gain on Payables Restructuring (Note G)	121,504
Settlement Expense (Note G)	(17,693)
Total Other Expense	213,587	138,193
Net (Loss) Income	(587,061)	176,641
Preferred Stock Dividends		64,622
(Loss) Income Attributable to Common Stockholders	$ (587,061)	$ 112,019
Weighted Average Outstanding Shares (in shares)	266,052,322	253,292,935
(Loss) Income Per Share Attributable to Common Stockholders (basic and diluted)	$ (0.0022)	$ 0.0004

Statements of Changes in Stockh

Statements of Changes in Stockholders' Equity - USD ($)	Preferred SharesSeries C Preferred Stock	Preferred SharesSeries B Preferred Stock	Common Stock	Accumulated Deficit	Total
Balance at Dec. 31, 2013	$ 160,000	$ 677,902	$ 26,368,892	$ (26,792,574)	$ 414,220
Balance (in shares) at Dec. 31, 2013	2,000,000	8,827,500	252,557,310
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Series C Preferred Stock Issued	$ 172,000				172,000
Series C Preferred Stock Issued (in shares)	4,640,000
Stock-based Compensation Expense for Directors and Consultants			$ 58,416		58,416
Stock-based Compensation Expense for Employees			$ 15,350		$ 15,350
Series B Preferred Stock Dividend Paid with Common Stock (in shares)
Series B Preferred Stock Annual Dividend			$ (64,622)		$ (64,622)
Series B Preferred Stock Exchanged for Common Stock		$ (677,902)	$ 677,902
Series B Preferred Stock Exchanged for Common Stock (in shares)		(8,827,500)	8,827,500
Net (Loss) Income				$ 176,641	176,641
Balance at Dec. 31, 2014	$ 332,000		$ 27,055,938	(26,615,933)	772,005
Balance (in shares) at Dec. 31, 2014	6,640,000		261,384,810
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Series C Preferred Stock Issued	$ 228,732				568,000
Series C Preferred Stock Issued (in shares)	23,360,000
Stock-based Compensation Expense for Directors and Consultants			$ 52,933		52,933
Stock-based Compensation Expense for Employees			15,350		15,350
Series B Preferred Stock Dividend Paid with Common Stock			$ 166,709		166,709
Series B Preferred Stock Dividend Paid with Common Stock (in shares)			3,334,179
Common Stock Issued			$ 120,000		120,000
Common Stock Issued (in shares)			4,000,000
Net (Loss) Income				(587,061)	(587,061)
Balance at Dec. 31, 2015	$ 560,732		$ 27,410,930	$ (27,202,994)	$ 768,668
Balance (in shares) at Dec. 31, 2015	30,000,000		268,718,989

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash Flows From Operating Activities
Net (Loss) Income	$ (587,061)	$ 176,641
Adjustments to Reconcile Net (Loss) Income to Net Cash Used in Operating Activities:
Stock-based Compensation for Employees	15,350	15,350
Stock-based Compensation for Directors and Consultants	52,933	58,416
Gain on Payables Restructuring (Note G)	(121,504)
Realized Gain on Investments in Available for Sale Securities Measured in Accordance with the Fair Value Option (Note J)	(232,937)	(338,087)
Unrealized Loss on Investments in Available for Sale Securities Measured in Accordance with the Fair Value Option (Note J)	123,161	199,894
Depreciation and Amortization	263,644	267,351
Decrease (Increase) in Accounts Receivable	1,969	(1,889)
Decrease in Deferred Revenue	(43,387)	(1,024,988)
Decrease in Accounts Payable - Trade	(80,773)	(86,357)
Decrease in Accrued Liabilities		(2,500)
Net Cash Used in Operating Activities	(608,605)	(736,169)
Cash Flows From Investing Activities:
Investing Activity - Purchase of Securities	(1,294)
Proceeds from Sale of Available for Sale Securities (Note J)	331,465	499,820
Net Cash Provided by Investing Activity	330,171	499,820
Cash Flows From Financing Activities:
Proceeds from Common Stock Issuance	120,000
Proceeds from Series C Preferred Stock Issuance	568,000	172,000
Net Cash Provided by Financing Activity	688,000	172,000
Net Increase (Decrease) in Cash	409,566	(64,349)
Cash, at Beginning of Period	7,642	71,991
Cash, at End of Period	$ 417,208	$ 7,642

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Note A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES DESCRIPTION OF BUSINESS Health Discovery Corporation (the “Company”) is a biotechnology-oriented company that has acquired patents and has patent pending applications for certain machine learning tools, primarily pattern recognition techniques using advanced mathematical algorithms to analyze large amounts of data thereby uncovering patterns that might otherwise be undetectable. Such machine learning tools are currently in use for diagnostics and drug discovery, but are also marketed for other applications. The Company licenses the use of its patent protected technology and may provide services to develop specific learning tools under development agreements or to sell to third parties. USE OF ESTIMATES The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Accordingly, actual results could differ from those estimates. Significant estimates that are particularly susceptible to change in the near-term include the valuation of share-based compensation and consideration for services and the recoverability of the patents. REVENUE RECOGNITION Revenue is generated through the sale or license of patented technology and processes and from services provided through development agreements. These arrangements are generally governed by contracts that dictate responsibilities and payment terms. The Company recognizes revenues as they are earned over the duration of a license agreement once all contractual obligations have been fulfilled. If a license agreement has an undetermined or unlimited life, the revenue is recognized over the remaining expected life of the patents. Revenue is recognized under development agreements in the period the services are performed. CASH Cash includes cash deposited with financial institutions. ACCOUNTS RECEIVABLE Trade accounts receivable for licensing fees and development services are recorded at net contract value based upon the written agreement with the customer. In certain cases, accounts receivable may include royalties receivable from customers based upon those customers estimated sales of the products or diagnostic tests containing patented processes and technologies. The Company considers amounts past due based on the related terms of the agreement and reviews its exposure to amounts receivable based upon collection history and specific customer credit analysis. The Company provides an allowance for doubtful amounts if collectability is no longer reasonably assured. There were no amounts outstanding as of December 31, 2015. As of December 31, 2014, all amounts receivable are considered fully collectable and no allowance for doubtful accounts was recorded. EQUIPMENT Equipment, which consists of office furniture, computer equipment, and leasehold improvements, are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 10 years. Leasehold improvements are amortized using the straight-line method over the estimated useful lives of the assets or the term of the lease, whichever is shorter. PATENTS Initial costs paid to purchase patents are capitalized and amortized using the straight line method over the remaining life of the patent. The Company capitalizes the external costs and filing fees associated with obtaining patents on its new discoveries and amortizes these costs using the straight-line method over the shorter of the legal life of the patent or its economic life, generally 17 years, beginning on the date the patent is issued. Annual patent maintenance costs and annual license and renewal registration fees are expensed as period costs. If the applied for patents are abandoned or are not issued, the Company will expense the costs capitalized to date in the period of abandonment or earlier if abandonment appears probable. The carrying value of patents is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. As of December 31, 2015, the Company does not believe there has been any impairment of its patents. INVESTMENTS The Company uses the equity method to account for its equity investments in ventures for which it has 50% or less ownership and the ability to exercise significant influence over operating and financial policies, but does not control. The Company uses the cost method to account for its investments in companies that it does not control and for which it does not have the ability to exercise significant influence over operating and financial policies. INCOME TAXES The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are recognized for future tax benefits and expenses or consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income for the years in which those temporary differences are expected to be recovered or settled. In the event the future tax consequences of differences between the financial reporting bases and tax bases of the Company’s assets and liabilities result in deferred tax assets, an evaluation is made of the probability of being able to realize the future benefits indicated by such assets. A valuation allowance is provided for the portion of the deferred tax asset when it is more likely than not that some portion or all of the deferred tax asset will not be realized. In assessing the probability of realizing the deferred tax assets, management considers the scheduled reversals of deferred tax liabilities, projected future taxable income, and tax planning strategies. STOCK-BASED COMPENSATION Stock-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the requisite service period. Valuation and Amortization Method Expected Term Expected Volatility – Risk-Free Interest Rate RESEARCH AND DEVELOPMENT EXPENSE The Company’s research and development costs are expensed as incurred and consist of expenses paid to consultants and external laboratories and related primarily to the costs of co-development studies, clinical trials, and projects undertaken. FAIR VALUE OF FINANCIAL INSTRUMENTS The Company’s financial instruments consist of cash, available for sale securities, accounts receivable, and accounts payable. The Company considers the carrying values of its financial instruments in the financial statements to approximate their fair value due to the short-term nature of such items. Refer to Note J for discussion regarding the valuation of the Company’s investment in available for sale securities. NET INCOME (LOSS) PER SHARE Basic Earnings Per Share (“EPS”) includes no dilution and is computed by dividing income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution of securities that could share in the earnings or losses of the entity. Due to the net loss for the year ended December 31, 2015, the calculation of diluted per share amounts would create an anti-dilutive result and therefore are not presented in the following table. Potentially dilutive shares at December 31, 2015, include options and warrants outstanding of 46,750,000. The following is an analysis of the basic and diluted earnings per common share computations for the year ended December 31, 2014: Year ended December 31, 2014 Basic: Net income attributable to common stockholders $ 112,019 Basic weighted average common shares outstanding 253,292,935 Net income per share attributable to common stockholders - basic $ 0.0004 Diluted: Net income attributable to common stockholders $ 112,019 Basic weighted average common shares outstanding 253,292,935 Effect of dilutive securities: Conversion of options and warrants - Conversion of preferred shares to common shares 6,640,000 Diluted weighted average common shares outstanding 259,932,935 Net income per share attributable to common stockholders - diluted $ 0.0004 During the year ended December 31, 2014, 19,390,000 outstanding stock options and warrants were not included in the computation of diluted earnings per common share because to do so would have an antidilutive effect. Please refer to Note H regarding detail for outstanding stock options. CONCENTRATIONS OF CREDIT RISK The Company maintains its cash balances at financial institutions that are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 per account. From time-to-time, the Company’s cash balances exceed the amount insured by the FDIC. Management believes the risk of loss of cash balances in excess of the insured limit to be low. RECENT ACCOUNTING PRONOUNCEMENTS In February 2016, the FASB issued Accounting Standards (“ASU”) 2016-02, Leases. This standard update was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including for operating leases, on the balance sheet and disclosing key information about leasing arrangements. ASU 2016-02 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the impact that adopting ASU 2016-02 will have on its consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. This standard update provides guidance for balance sheet classification of deferred taxes. This standard requires that deferred tax assets and liabilities be classified as non-current on the balance sheet, and eliminates the prior guidance which required an entity to separate deferred tax liabilities and assets into a current amount and a noncurrent amount on the balance sheet. ASU 2015-17 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Earlier application is permitted as of the beginning of an interim or annual period. The Company is currently evaluating the impact that adopting ASU 2015-17 will have on its consolidated financial statements COMMON STOCK WARRANTS LIABILITY In September 2015, the Company completed a private placement of 30,000,000 shares of preferred stock as well as a private placement of 4,000,000 shares of common stock and issued warrants to purchase an additional 34,000,000 shares of common stock. Due to the warrant features that accompany the sale of the Company’s preferred and common shares, if all outstanding options and warrants were exercised, the Company would not have sufficient shares of common stock to meet the exercised options and warrants. As a result, these warrants are required to be classified as a liability. The common stock warrants liability is recorded based upon the number of warrants which exceed the number of common shares available to meet the exercised options and warrants using the Black-Scholes option-pricing model.

DEFERRED REVENUE

DEFERRED REVENUE	12 Months Ended
	Dec. 31, 2015
Deferred Revenue Disclosure [Abstract]
DEFERRED REVENUE	Note B – DEFERRED REVENUE Deferred revenue represents the unearned portion of payments received in advance for licensing or service agreements. The Company received $2,944,800 as a part of the NeoGenomics license agreement in January 2012. Deferred revenue of $2,944,800 was recorded and recognized as income over the three years of the term of the license agreement, which ended in January 2015. The remaining amount of deferred revenue relates to the Company’s settlement with Vermillion. The Company had total unearned revenue of $148,241 as of December 31, 2015. The long-term portion of unearned revenue represents the remaining term of the agreements or the remaining lives of the underlying patents, as appropriate, and ranges from one to seven years. The expected future annual recognition of revenue is as follows: 2016 $ 43,388 2017 43,388 2018 43,388 2019 18,077 Total expected future annual amortization $ 148,241

PATENTS

PATENTS	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
PATENTS	Note C – PATENTS The Company has acquired a group of patents related to biotechnology and certain machine learning tools used for diagnostic and drug discovery. The cost and accumulated amortization as of December 31, 2015 and 2014 are as follows: 2015 2014 Cost of Patents $ 3,985,794 $ 3,985,794 Accumulated Amortization (3,044,728 ) (2,782,009 ) Patents, Net of Amortization $ 941,066 $ 1,203,785 Amortization charged to operations for each of the years ended December 31, 2015 and 2014 was $262,719. The weighted average remaining amortization period for patents at December 31, 2015 is 3.60 years. Estimated amortization expense for the next three years is $262,719 per year.

INVESTMENTS

INVESTMENTS	12 Months Ended
	Dec. 31, 2015
Investments, Debt and Equity Securities [Abstract]
INVESTMENTS	Note D – INVESTMENTS On March 27, 2007, the Company and an investment partner formed SVM Capital, LLC (“SVM Capital”) as an equity investment for purposes of utilizing SVM as a quantitative investment management technique. The Company owns 45% of the membership interest and has significant influence with the operation of the entity but does not have control over the entity. The Company does not have any obligation to fund or provide support to SVM Capital. Accordingly, the investment is accounted for using the equity method of accounting. The Company’s initial investment was $5,000 and the license to use the SVM technology applied to financial markets. The carrying value of this investment was zero as of December 31, 2015 and 2014.

LICENSE FEES EXPENSE - LUCENT A

LICENSE FEES EXPENSE - LUCENT AGREEMENT	12 Months Ended
	Dec. 31, 2015
License Agreement [Abstract]
LICENSE FEES EXPENSE - LUCENT AGREEMENT	Note E – LICENSE FEES EXPENSE - LUCENT AGREEMENT Effective September 26, 2004, the Company was assigned a patent license agreement with Lucent Technologies GRL Corporation (“Lucent”). The patent license agreement was associated with the patents acquired July 30, 2004. The Company agreed to pay royalty fees to Lucent in the amount of the greater of an annual fee of $10,000 or at the rate of five percent (5%) on each licensed product which is sold, leased, or put into use by the Company, until cumulative royalties equal $40,000 and at the rate of one percent (1%) subsequently. The license granted will continue for the entire unexpired term of Lucent’s patents. During 2014, the Company paid $6,095 in royalty fees to Lucent. The Lucent patents expired in July 2014, and therefore the license agreement with Lucent expired. The Company is no longer required to make royalty payments to Lucent.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
INCOME TAXES	Note F – INCOME TAXES The Company has incurred net losses since inception, and we have determined that it is more likely than not we will be unable to benefit in the future from the accumulated net operating loss (“NOL”). Consequently, we have not recorded any U.S. federal or state income tax expense or benefit. We have not recorded income tax expense or benefit for the fiscal years ending December 31, 2015 or 2014 due to a full valuation allowance for any NOL’s that would have been generated or used. The following items comprise the Company’s net deferred tax assets (liabilities) as of December 31, 2015 and 2014: 2015 2014 Deferred tax assets: Net operating losses $ 8,026,288 $ 7,877,660 Deferred revenue 50,402 65,154 Stock compensation 410,550 55,991 Deferred tax asset 8,487,240 7,998,805 Deferred tax liabilities: Depreciation and amortization (4,007 ) (4,007 ) Unrealized gain (39,413 ) (80,956 ) Deferred tax liability (43,420 ) (84,963 ) Net deferred tax asset 8,443,820 7,913,842 Less valuation allowance (8,443,820 ) (7,913,842 ) Net deferred taxes $ - $ - For the year ended December 31, 2015, an increase in the valuation allowance of $529,978 has been recorded for the deferred tax asset, as management has determined that it is more likely than not that the deferred tax asset will not be realized. Total income tax expense (benefit) differed from the amounts computed by applying the U.S. Federal statutory tax rates to pre-tax loss for the fiscal years ended December 31, 2015 and 2014, as follows: 2015 2014 Total benefit computed by: Applying the U.S. Federal statutory rate (34 )% (34 )% State income taxes, net of federal tax benefit (3 )% (3 )% Valuation allowance 37 % 37 % Effective tax rate - - The Company has unused net operating loss carry-forwards of approximately $23.6 million that are available to offset future income tax expense. The net operating losses will begin to expire in 2020. Based on its evaluation of tax positions, the Company has concluded that there are no significant uncertain tax positions requiring recognition in its financial statements. The Company’s evaluation was performed for all tax years, which remain subject to examination and adjustment, by major tax jurisdictions as of December 31, 2015. The Company is generally no longer subject to U.S. federal, state, and local, or non-US income tax examinations for the years before 2012.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	Note G – COMMITMENTS AND CONTINGENCIES Operating Lease The Company does not own any real property. The Company leases approximately 350 square feet of office space in Atlanta, Georgia, pursuant to a month-to-month lease dated April 1, 2013. The Company currently pays base rent in the amount of $600 per month. Legal Issues On July 17, 2013, the Company received a Civil Investigative Demand (the "Demand") from the Federal Trade Commission of the United States of America (the "FTC") relating to the Company's MelApp software application. In the Demand, the FTC has requested information relating to potentially unfair or deceptive acts or practices related to (i) false advertising and (ii) consumer privacy and data security, in violation of Trade Commission Act, 15 U.S.C. Sections 45 and 42. On February 23, 2015, the FTC notified the Company of its approval, by a vote of 4-1, to accept an Agreement Containing Consent Order (“Agreement”). The Agreement , among other things, bars the Company from claiming that any device detects or diagnoses melanoma or its risk factors, or increases users’ chances of early detection, unless the representation is not misleading and supported by competent and reliable scientific evidence in the form of human clinical testing of the device. The Agreement also prohibits the Company from making any other misleading or unsubstantiated claims about a device’s health benefits or efficacy, unless the representation is not misleading and supported by competent and reliable scientific evidence in the form of human clinical testing of the device. Finally, the Company was required to pay $17,693 to the FTC. The Company made this payment on April 16, 2015. This amount is included as Settlement Expense in the accompanying statements of operations. The Company’s balance sheet for the year ended December 31, 2014 reflected accounts payable of approximately $239,910 for professional services. In an effort to conserve cash, the Company negotiated with certain of the service providers regarding potential reduction of the amount billed. During the quarter ended September 30, 2015, the Company and the service providers successfully renegotiated the amounts owed and as a result, the Company recorded a decrease in accounts payables of $121,504. The Company is subject to various claims primarily arising in the normal course of business. Although the outcome of these matters cannot be determined, the Company does not believe it is probable that any such claims will result in material costs and expenses.

STOCK COMPENSATION AND EQUITY B

STOCK COMPENSATION AND EQUITY BASED PAYMENTS	12 Months Ended
	Dec. 31, 2015
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
STOCK COMPENSATION AND EQUITY BASED PAYMENTS	Note H – STOCK COMPENSATION AND EQUITY BASED PAYMENTS Information about options and warrants outstanding for 2015 and 2014 is summarized below: Number of Warrants and Options Issued 2015 Weighted Average Exercise Price 2014 Weighted Average Exercise Price Outstanding beginning of year 19,390,000 $ 0.034 13,500,000 $ 0.050 Granted 27,360,000 0.030 6,640,000 0.030 Exercised - - - - Forfeited - - - - Expired un-exercised - - (750,000 ) 0.080 Outstanding end of the year 46,750,000 $ 0.032 19,390,000 $ 0.034 Exercisable December 31 39,916,668 $ 0.032 13,723,335 $ 0.034 The following schedule summarizes combined stock option and warrant information as of December 31, 2015. Exercise Prices Number Outstanding Weighted- Average Remaining Contractual Life (years) Number Exercisable Weighted Average Remaining Contractual Life (years) of Exercisable Warrants $0.027 3,000,000 7.50 2,000,000 7.50 $0.030 34,000,000 8.50 34,000,000 8.50 $0.036 7,750,000 7.75 5,875,000 7.75 $0.040 1,000,000 2.00 1,000,000 2.00 $0.050 1,000,000 2.00 1,000,000 2.00 Total 46,750,000 39,916,668 As of December 31, 2015, there was $51,892 of unrecognized cost related to stock option and warrant grants. The cost is to be recognized over the remaining vesting periods that average approximately nine months. The weighted average remaining life of all outstanding warrants and options at December 31, 2015 are 7.5 years. The aggregate intrinsic value of all options and warrants outstanding and exercisable as of December 31, 2015 was $6,000, based on the market closing price of $0.03 on December 31, 2015, less exercise prices. Stock-based expense included in the 2015 net loss consisted of $68,283 in directors, employees and consultants option expenses for services. Specifically, director option expenses were $33,198 and common stock issued for service expenses related to employees and consultants were $35,085. During 2014, stock-based expense included in the net income consisted of $73,766. Specifically, director option expenses were $33,199 and option expenses related to employees and consultants were $40,567. The following table reflects stock-based compensation and expense recorded in 2015 and 2014: 2015 2014 Director and consultant option expenses $ 52,933 $ 58,416 Employee option expenses 15,350 15,350 Total stock compensation expenses $ 68,283 $ 73,766 In connection with their election to the Board of Directors, on July 25, 2013, the Company granted to Mr. Henry Kaplan, Mr. Kevin Kowbel, and Mr. Eric Winger each an option to purchase 1,500,000 shares of the Company’s common stock. Upon his appointment to Interim Chief Executive Officer, Mr. Kowbel returned his options back to the Company. As a result, only the options for Messrs. Kaplan and Winger vest 250,000 shares every six months, have an exercise price of $0.027, and expire on July 25, 2023. The fair value of each option granted is $0.020 and was estimated on the date of grant using the Black-Scholes pricing model with the following assumptions: dividend yield at 0%, risk-free interest rate of 1.91%, an expected life of 5 years, and volatility of 98%. The aggregate computed fair value of these options is $60,124, and this amount is charged as an expense over the three-year vesting period. There is no expense related to Mr. Kowbel as he returned all of the options granted to him back to the Company. In connection with his appointment to the Board of Directors in July 2013, on October 21, 2013, Mr. William F. Quirk, Jr. was granted an option to purchase 1,500,000 shares of the Company’s common stock. This option grant is consistent with what has been granted to other board members. The options vest 250,000 shares every six months, have an exercise price of $0.036, and expire on October 21, 2023. The non-cash charge of $39,471 for the fair value of these options will be recognized as an expense over the three-year vesting period. Also, on October 21, 2013, the Company granted options to purchase 6,000,000 shares of the Company’s common stock to a group of employees and consultants in recognition of their efforts to lower the Company’s monthly expenditures and compensation and their continuing contributions to the Company. The options vest over a three-year period, have an exercise price of $.036, and expire on October 21, 2023. Within the group of 6,000,000 options, the Company’s Vice President, Mark A. Moore, Ph.D., received an option to purchase 1,000,000 shares of the Company’s common stock and the Company’s Senior Vice President, Hong Zhang, Ph.D., received an option to purchase 750,000 shares of the Company’s common stock. The non-cash charge of $203,931 for the fair value of these options will be recognized as an expense over the three-year vesting period.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2015
Stockholders Equity Note [Abstract]
STOCKHOLDERS' EQUITY	Note I - STOCKHOLDERS’ EQUITY Series B Preferred Stock The Company sold to individual investors a total of 19,402,675 shares of Series B Preferred Stock for $1,490,015, net of associated expenses, in 2009. The Series B Preferred Stock was converted into Common Stock of the Company in the fourth quarter of 2014, which was the fifth anniversary of the date of issuance as outlined in the original purchase agreement. Dividends have been accrued for the Series B Preferred Stock in the amount of $373,346 as of December 31, 2014. The Company gave the Series B holders the choice of either (1) Common Stock for the amount of the dividend accrued based upon the price of $0.05 per share or (2) to defer payment of the dividend in cash until the Company is able to pay, at the sole discretion of the Company. During the first quarter of 2015, $166,709 in dividends were paid with the issuance of 3,334,179 shares of Common Stock. The remaining accrued dividend is recorded as a current liability in the amount of $206,637 as of December 31, 2015. Series C Preferred Stock In the fourth quarter of 2013, the Board of Directors authorized the issuance of Series C Preferred Shares in private placement transactions. As of December 31, 2014 and 2015, the Company had issued a total of 6,640,000 and 30,000,000 preferred shares, respectively. The Series C Preferred Shares were fully subscribed in the third quarter 2015. The Company received total net proceeds of $560,732. The Series C Preferred Shares are accompanied by $0.03 warrants and $0.03 contingency warrants. The contingency warrants will be issued only if the Company has not attained profitability by the end of the first quarter 2016. The holders must exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.20 for a period of thirty consecutive calendar days. The holders must also exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.30 for a period of thirty consecutive calendar days. The warrants were valued at $0.022 each using the Black Scholes Method. The Series C Preferred Stock has not been registered under either federal or state securities laws and must be held until a registration statement covering such securities is declared effective by the Securities and Exchange Commission or an applicable exemption applies. The Series C Preferred Stock may be converted into Common Stock of the Company at the option of the holder, without the payment of additional consideration by the holder, so long as the Company has a sufficient number of authorized shares to allow for the exercise of all of its outstanding warrants and options. The Shares of Series C Preferred Stock must be converted into Common Stock of the Company either by the demand by the shareholder or at the fifth anniversary of the date of issuance. If the Company were to be dissolved, the Series C Preferred Stock receives preferential treatment over Common Stock. During the third quarter of 2015, the Board of Directors authorized the issuance of Common Stock in a private placement of 7,000,000 Common Shares with certain warrant features. As of December 31, 2015, 4,000,000 shares of this offering were sold and the Company received proceeds of $120,000. The Common Shares are accompanied by $0.03 warrants and $0.06 contingency warrants. The contingency warrants will be issued only if the Company has not attained profitability by the end of the first quarter 2016. The holders must exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.20 for a period of thirty consecutive calendar days. The holders must also exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.30 for a period of thirty consecutive calendar days. The warrants were valued at $0.022 each using the Black Scholes Method. Due to the warrant features that accompany the sale of the Company’s preferred and common shares, if all outstanding options and warrants were exercised, the Company would not have sufficient shares of common stock to meet the exercised options. The aggregate intrinsic value of all options and warrants outstanding and exercisable as of December 31, 2015 was zero, based on the market closing price of $0.03 on December 31, 2015, less exercise prices. The Company will need to increase the authorized shares of common stock in order to satisfy the options and warrants if the holders exercise the outstanding options and warrants.

INVESTMENT IN AVAILABLE FOR SAL

INVESTMENT IN AVAILABLE FOR SALE SECURITIES	12 Months Ended
	Dec. 31, 2015
Available-For-Sale Securities [Abstract]
INVESTMENT IN AVAILABLE FOR SALE SECURITIES	Note J – INVESTMENT IN AVAILABLE FOR SALE SECURITIES The Company has elected the fair value option in accordance with ASC 825, Financial Instruments, The Company’s investment in NeoGenomics’ common stock is recorded on the accompanying balance sheets under the caption Investment in Available for Sale Securities. The carrying value of this investment on the date of acquisition approximated $1,945,000. The change in fair value from the December 31, 2014 to December 31, 2015 is an unrecognized loss of $123,161 for the remaining 18,000 shares held and is classified as other expense under the caption Unrealized Loss on Available for Sale Securities in the accompanying statements of operations. There are three levels of investments in the fair value hierarchy that assesses a company's assets based on the degree of certainty around the asset's underlying value. Level 1 asset can be valued with certainty because they are liquid and have clear market prices. At the other end of the spectrum, Level 3 assets are illiquid and estimating their value requires inputs that are unobservable and reflect management assumptions. The Company classifies its investment as an available for sale security presented as a trading security on the balance sheet and the fair value is considered a Level 1 investment in the fair value hierarchy. The December 31, 2015 fair value of the investment of $141,978 is for the remaining shares held and is calculated using the closing stock price of the NeoGenomics common stock at the end of the reporting period. During 2015, the Company sold 68,900 shares of NeoGenomics and received proceeds in the amount of $331,465. These transactions resulted in the Company recognizing a Realized Gain on the Sale of Available for Sale Securities in the accompanying statements of operations in the amount of $232,937 in the current period. As of December 31, 2015, the Company held 18,000 shares of NeoGenomics stock as compared to 86,900 shares as of December 31, 2014. The initial 1,360,000 shares were acquired in January 2012 as a result of the NeoGenomics Master License Agreement.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	Note K – SUBSEQUENT EVENTS On February 8, 2016, the Company granted options to purchase 5,000,000 shares of the Company’s common stock to a group of employees and consultants in recognition of their efforts to lower the Company’s monthly expenditures and compensation and their continuing contributions to the Company. The options vest over a two-year period, have an exercise price of $.03, and expire on February 8, 2026. Within the group of 5,000,000 options, the Company’s Vice President, Mark A. Moore, Ph.D., received an option to purchase 500,000 shares of the Company’s common stock and the Company’s Senior Vice President, Hong Zhang, Ph.D., received an option to purchase 1,250,000 shares of the Company’s common stock. The non-cash charge of $109,721 for the fair value of these options will be recognized as an expense over the two-year vesting period.

FINANCIAL CONDITION AND GOING C

FINANCIAL CONDITION AND GOING CONCERN	12 Months Ended
	Dec. 31, 2015
Financial Condition and Going Concern [Abstract]
FINANCIAL CONDITION AND GOING CONCERN	Note L – FINANCIAL CONDITION AND GOING CONCERN The Company has prepared its financial statements on a “going concern” basis, which presumes that it will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future. The Company’s ability to continue as a going concern is dependent upon our licensing arrangements with third parties, achieving profitable operations, obtaining additional financing and successfully bringing the Company’s technologies to the market. The outcome of these matters cannot be predicted at this time. The Company’s financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classifications of the assets and liabilities that might be necessary should the Company be unable to continue in business. If the going concern assumption was not appropriate for the Company’s financial statements then adjustments would be necessary in the carrying value of assets and liabilities, the reported expenses and the balance sheet classifications used. Such adjustments may be material. At December 31, 2015 the Company had $417,208 cash on hand along with its investment in NeoGenomics stock available for sale securities worth $141,978. As a result, the Company estimates cash will be depleted by the end of 2016 if the Company does not generate sufficient cash to support operations. The Company’s plan to have sufficient cash to support operations is comprised of generating revenue through its relationship with NeoGenomics, providing services related to those patents, selling its NeoGenomics stock, and obtaining additional equity or debt financing. Specifically, the Company expects to begin receiving revenue from commercialization of the flow cytometry service and prostate tests developed as a part of the NeoGenomics relationship. As a result, the Company focused its efforts to secure funds via licensing activity or other forms of fund raising either in the debt or equity markets. In addition, prior to the beginning of this year, the Company began raising capital through the Series C Preferred Stock offering. The Series C Preferred Stock offering was fully subscribed and completed in August 2015. As a result, the Company received $568,000 in 2015 in addition to the $332,000 received in prior years for a total of $900,000. The Company believes the funds received from the Series C Preferred Stock offering, along with disciplined expense management, will allow the Company to maintain operations until the end of 2016. While the Company believes these efforts will create a profitable future, there is no guarantee the Company will be successful in these efforts.

SUMMARY OF SIGNIFICANT ACCOUN19

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
USE OF ESTIMATES	USE OF ESTIMATES The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Accordingly, actual results could differ from those estimates. Significant estimates that are particularly susceptible to change in the near-term include the valuation of share-based compensation and consideration for services and the recoverability of the patents.
REVENUE RECOGNITION	REVENUE RECOGNITION Revenue is generated through the sale or license of patented technology and processes and from services provided through development agreements. These arrangements are generally governed by contracts that dictate responsibilities and payment terms. The Company recognizes revenues as they are earned over the duration of a license agreement once all contractual obligations have been fulfilled. If a license agreement has an undetermined or unlimited life, the revenue is recognized over the remaining expected life of the patents. Revenue is recognized under development agreements in the period the services are performed.
CASH	CASH Cash includes cash deposited with financial institutions.
ACCOUNTS RECEIVABLE	ACCOUNTS RECEIVABLE Trade accounts receivable for licensing fees and development services are recorded at net contract value based upon the written agreement with the customer. In certain cases, accounts receivable may include royalties receivable from customers based upon those customers estimated sales of the products or diagnostic tests containing patented processes and technologies. The Company considers amounts past due based on the related terms of the agreement and reviews its exposure to amounts receivable based upon collection history and specific customer credit analysis. The Company provides an allowance for doubtful amounts if collectability is no longer reasonably assured. There were no amounts outstanding as of December 31, 2015. As of December 31, 2014, all amounts receivable are considered fully collectable and no allowance for doubtful accounts was recorded.
EQUIPMENT	EQUIPMENT Equipment, which consists of office furniture, computer equipment, and leasehold improvements, are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 10 years. Leasehold improvements are amortized using the straight-line method over the estimated useful lives of the assets or the term of the lease, whichever is shorter.
PATENTS	PATENTS Initial costs paid to purchase patents are capitalized and amortized using the straight line method over the remaining life of the patent. The Company capitalizes the external costs and filing fees associated with obtaining patents on its new discoveries and amortizes these costs using the straight-line method over the shorter of the legal life of the patent or its economic life, generally 17 years, beginning on the date the patent is issued. Annual patent maintenance costs and annual license and renewal registration fees are expensed as period costs. If the applied for patents are abandoned or are not issued, the Company will expense the costs capitalized to date in the period of abandonment or earlier if abandonment appears probable. The carrying value of patents is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. As of December 31, 2015, the Company does not believe there has been any impairment of its patents.
INVESTMENTS	INVESTMENTS The Company uses the equity method to account for its equity investments in ventures for which it has 50% or less ownership and the ability to exercise significant influence over operating and financial policies, but does not control. The Company uses the cost method to account for its investments in companies that it does not control and for which it does not have the ability to exercise significant influence over operating and financial policies.
INCOME TAXES	INCOME TAXES The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are recognized for future tax benefits and expenses or consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income for the years in which those temporary differences are expected to be recovered or settled. In the event the future tax consequences of differences between the financial reporting bases and tax bases of the Company’s assets and liabilities result in deferred tax assets, an evaluation is made of the probability of being able to realize the future benefits indicated by such assets. A valuation allowance is provided for the portion of the deferred tax asset when it is more likely than not that some portion or all of the deferred tax asset will not be realized. In assessing the probability of realizing the deferred tax assets, management considers the scheduled reversals of deferred tax liabilities, projected future taxable income, and tax planning strategies.
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION Stock-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the requisite service period. Valuation and Amortization Method Expected Term Expected Volatility – Risk-Free Interest Rate
RESEARCH AND DEVELOPMENT EXPENSE	RESEARCH AND DEVELOPMENT EXPENSE The Company’s research and development costs are expensed as incurred and consist of expenses paid to consultants and external laboratories and related primarily to the costs of co-development studies, clinical trials, and projects undertaken.
FAIR VALUE OF FINANCIAL INSTRUMENTS	FAIR VALUE OF FINANCIAL INSTRUMENTS The Company’s financial instruments consist of cash, available for sale securities, accounts receivable, and accounts payable. The Company considers the carrying values of its financial instruments in the financial statements to approximate their fair value due to the short-term nature of such items. Refer to Note J for discussion regarding the valuation of the Company’s investment in available for sale securities.
NET INCOME (LOSS) PER SHARE	NET INCOME (LOSS) PER SHARE Basic Earnings Per Share (“EPS”) includes no dilution and is computed by dividing income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution of securities that could share in the earnings or losses of the entity. Due to the net loss for the year ended December 31, 2015, the calculation of diluted per share amounts would create an anti-dilutive result and therefore are not presented in the following table. Potentially dilutive shares at December 31, 2015, include options and warrants outstanding of 46,750,000. The following is an analysis of the basic and diluted earnings per common share computations for the year ended December 31, 2014: Year ended December 31, 2014 Basic: Net income attributable to common stockholders $ 112,019 Basic weighted average common shares outstanding 253,292,935 Net income per share attributable to common stockholders - basic $ 0.0004 Diluted: Net income attributable to common stockholders $ 112,019 Basic weighted average common shares outstanding 253,292,935 Effect of dilutive securities: Conversion of options and warrants - Conversion of preferred shares to common shares 6,640,000 Diluted weighted average common shares outstanding 259,932,935 Net income per share attributable to common stockholders - diluted $ 0.0004 During the year ended December 31, 2014, 19,390,000 outstanding stock options and warrants were not included in the computation of diluted earnings per common share because to do so would have an antidilutive effect. Please refer to Note H regarding detail for outstanding stock options.
CONCENTRATIONS OF CREDIT RISK	CONCENTRATIONS OF CREDIT RISK The Company maintains its cash balances at financial institutions that are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 per account. From time-to-time, the Company’s cash balances exceed the amount insured by the FDIC. Management believes the risk of loss of cash balances in excess of the insured limit to be low.
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS In February 2016, the FASB issued Accounting Standards (“ASU”) 2016-02, Leases. This standard update was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including for operating leases, on the balance sheet and disclosing key information about leasing arrangements. ASU 2016-02 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the impact that adopting ASU 2016-02 will have on its consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. This standard update provides guidance for balance sheet classification of deferred taxes. This standard requires that deferred tax assets and liabilities be classified as non-current on the balance sheet, and eliminates the prior guidance which required an entity to separate deferred tax liabilities and assets into a current amount and a noncurrent amount on the balance sheet. ASU 2015-17 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Earlier application is permitted as of the beginning of an interim or annual period. The Company is currently evaluating the impact that adopting ASU 2015-17 will have on its consolidated financial statements
COMMON STOCK WARRANTS LIABILITY	COMMON STOCK WARRANTS LIABILITY In September 2015, the Company completed a private placement of 30,000,000 shares of preferred stock as well as a private placement of 4,000,000 shares of common stock and issued warrants to purchase an additional 34,000,000 shares of common stock. Due to the warrant features that accompany the sale of the Company’s preferred and common shares, if all outstanding options and warrants were exercised, the Company would not have sufficient shares of common stock to meet the exercised options and warrants. As a result, these warrants are required to be classified as a liability. The common stock warrants liability is recorded based upon the number of warrants which exceed the number of common shares available to meet the exercised options and warrants using the Black-Scholes option-pricing model.

SUMMARY OF SIGNIFICANT ACCOUN20

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Schedule of basic and diluted earnings per common share	Year ended December 31, 2014 Basic: Net income attributable to common stockholders $ 112,019 Basic weighted average common shares outstanding 253,292,935 Net income per share attributable to common stockholders - basic $ 0.0004 Diluted: Net income attributable to common stockholders $ 112,019 Basic weighted average common shares outstanding 253,292,935 Effect of dilutive securities: Conversion of options and warrants - Conversion of preferred shares to common shares 6,640,000 Diluted weighted average common shares outstanding 259,932,935 Net income per share attributable to common stockholders - diluted $ 0.0004

DEFERRED REVENUE (Tables)

DEFERRED REVENUE (Tables)	12 Months Ended
	Dec. 31, 2015
Deferred Revenue Disclosure [Abstract]
Schedule of expected future annual recognition of revenue	2016 $ 43,388 2017 43,388 2018 43,388 2019 18,077 Total expected future annual amortization $ 148,241

PATENTS (Tables)

PATENTS (Tables)	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of cost and accumulated amortization	2015 2014 Cost of Patents $ 3,985,794 $ 3,985,794 Accumulated Amortization (3,044,728 ) (2,782,009 ) Patents, Net of Amortization $ 941,066 $ 1,203,785

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of deferred tax assets and liabilities	2015 2014 Deferred tax assets: Net operating losses $ 8,026,288 $ 7,877,660 Deferred revenue 50,402 65,154 Stock compensation 410,550 55,991 Deferred tax asset 8,487,240 7,998,805 Deferred tax liabilities: Depreciation and amortization (4,007 ) (4,007 ) Unrealized gain (39,413 ) (80,956 ) Deferred tax liability (43,420 ) (84,963 ) Net deferred tax asset 8,443,820 7,913,842 Less valuation allowance (8,443,820 ) (7,913,842 ) Net deferred taxes $ - $ -
Schedule of income tax expense (Benefit)	2015 2014 Total benefit computed by: Applying the U.S. Federal statutory rate (34 )% (34 )% State income taxes, net of federal tax benefit (3 )% (3 )% Valuation allowance 37 % 37 % Effective tax rate - -

STOCK COMPENSATION AND EQUITY24

STOCK COMPENSATION AND EQUITY BASED PAYMENTS (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
Schedule of stock option and warrant information of the company	Number of Warrants and Options Issued 2015 Weighted Average Exercise Price 2014 Weighted Average Exercise Price Outstanding beginning of year 19,390,000 $ 0.034 13,500,000 $ 0.050 Granted 27,360,000 0.030 6,640,000 0.030 Exercised - - - - Forfeited - - - - Expired un-exercised - - (750,000 ) 0.080 Outstanding end of the year 46,750,000 $ 0.032 19,390,000 $ 0.034 Exercisable December 31 39,916,668 $ 0.032 13,723,335 $ 0.034
Schedule of combined stock option and warrant information of the company	Exercise Prices Number Weighted- Number Weighted $0.027 3,000,000 7.50 2,000,000 7.50 $0.030 34,000,000 8.50 34,000,000 8.50 $0.036 7,750,000 7.75 5,875,000 7.75 $0.040 1,000,000 2.00 1,000,000 2.00 $0.050 1,000,000 2.00 1,000,000 2.00 Total 46,750,000 39,916,668
Schedule of stock-based compensation and expense	2015 2014 Director and consultant option expenses $ 52,933 $ 58,416 Employee option expenses 15,350 15,350 Total stock compensation expenses $ 68,283 $ 73,766

SUMMARY OF SIGNIFICANT ACCOUN25

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Basic:
Net income attributable to common stockholders	$ (587,061)	$ 112,019
Basic weighted average common shares outstanding		253,292,935
Net income per share attributable to common stockholders - basic		$ 0.0004
Diluted:
Net income attributable to common stockholders		$ 112,019
Basic weighted average common shares outstanding		253,292,935
Effect of dilutive securities:
Conversion of options and warrants
Conversion of preferred shares to common shares		$ 6,640,000
Diluted weighted average common shares outstanding		259,932,935
Net income per share attributable to common stockholders - diluted		$ 0.0004

SUMMARY OF SIGNIFICANT ACCOUN26

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Estimated useful life of property and equipment	3 to 10 years
Maximum ownership in equity investments in ventures	50.00%
Research and development costs	$ 40,813	$ 99,200
Potentially dilutive shares include options and warrants outstanding	46,750,000
Outstanding stock options and warrants not included in computation of diluted earnings per common share		19,390,000
Cash balances at financial institutions that are insured by the Federal Deposit Insurance Corporation per account	$ 250,000

SUMMARY OF SIGNIFICANT ACCOUN27

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals 1)	12 Months Ended
	Dec. 31, 2015
Patents
Finite-Lived Intangible Assets [Line Items]
Useful life of finite-lived intangible assets	17 years

SUMMARY OF SIGNIFICANT ACCOUN28

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals 2) - Private placement - shares	1 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2015
Significant Accounting Policies [Line Items]
Number of shares issued under private placement		4,000,000
Share issued warrants to purchase	34,000,000
Preferred stock
Significant Accounting Policies [Line Items]
Number of shares issued under private placement	30,000,000
Common stock
Significant Accounting Policies [Line Items]
Number of shares issued under private placement	4,000,000

DEFERRED REVENUE - Expected fut

DEFERRED REVENUE - Expected future annual recognition of revenue (Details)	1 Months Ended
	Sep. 30, 2015USD ($)
Deferred Revenue Disclosure [Abstract]
2,016	$ 43,388
2,017	43,388
2,018	43,388
2,019	18,077
Total expected future annual amortization	$ 148,241

DEFERRED REVENUE (Detail Textua

DEFERRED REVENUE (Detail Textuals) - USD ($)	1 Months Ended	12 Months Ended
	Jan. 31, 2012	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Total unearned revenue		$ 148,241
NeoGenomics Master License Agreement
Finite-Lived Intangible Assets [Line Items]
Deferred revenue received in cash	$ 2,944,800
Period to recognize deferred revenue as income	3 years
Deferred revenue recorded and recognized as income	$ 2,944,800
Underlying Patents
Finite-Lived Intangible Assets [Line Items]
Estimated remaining term of the underlying patents		3 years 7 months 6 days
Underlying Patents | Minimum | NeoGenomics Master License Agreement
Finite-Lived Intangible Assets [Line Items]
Estimated remaining term of the underlying patents		1 year
Underlying Patents | Maximum | NeoGenomics Master License Agreement
Finite-Lived Intangible Assets [Line Items]
Estimated remaining term of the underlying patents		7 years

PATENTS (Details)

PATENTS (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Cost of Patents	$ 3,985,794	$ 3,985,794
Accumulated Amortization	(3,044,728)	(2,782,009)
Patents, Net of Amortization	$ 941,066	$ 1,203,785

PATENTS (Detail Textuals)

PATENTS (Detail Textuals) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Amortization charged to operations	$ 262,719	$ 262,719
Patents
Finite-Lived Intangible Assets [Line Items]
Amortization charged to operations	$ 262,719	262,719
Weighted average remaining amortization period	3 years 7 months 6 days
Estimated future amortization expense year 1		262,719
Estimated future amortization expense year 2		262,719
Estimated future amortization expense year 3		$ 262,719

INVESTMENT (Detail Textuals 1)

INVESTMENT (Detail Textuals 1) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Mar. 27, 2007
Schedule of Equity Method Investments [Line Items]
Percentage of membership interest	50.00%
SVM Capital LLC
Schedule of Equity Method Investments [Line Items]
Percentage of membership interest			45.00%
Carrying value of investment	$ 0	$ 0
Amount of initial investment			$ 5,000

LICENSE FEES EXPENSE - LUCENT34

LICENSE FEES EXPENSE - LUCENT AGREEMENT (Detail Textuals) - Patent License Agreement - Lucent Technologies GRL Corporation - USD ($)	1 Months Ended	12 Months Ended
	Sep. 26, 2004	Dec. 31, 2014
Agreement [Line Items]
Description of condition for royalty payment	The Company agreed to pay royalty fees to Lucent in the amount of the greater of an annual fee of $10,000 or at the rate of five percent (5%) on each licensed product which is sold, leased, or put into use by the Company, until cumulative royalties equal $40,000 and at the rate of one percent (1%) subsequently.
Royalty, annual fee	$ 10,000
Annual fee rate	5.00%
Cumulative royalties	$ 40,000
Cumulative royalties rate	1.00%
Royalty fees paid		$ 6,095

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Net operating losses	$ 8,026,288	$ 7,877,660
Deferred revenue	50,402	65,154
Stock compensation	410,550	55,991
Deferred tax asset	8,487,240	7,998,805
Deferred tax liabilities:
Depreciation and amortization	(4,007)	(4,007)
Unrealized gain	(39,413)	(80,956)
Deferred tax liability	(43,420)	(84,963)
Net deferred tax asset	8,443,820	7,913,842
Less valuation allowance	$ (8,443,820)	$ (7,913,842)
Net deferred taxes

INCOME TAXES (Details 1)

INCOME TAXES (Details 1)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Applying the U.S. Federal statutory rate	(34.00%)	(34.00%)
State income taxes, net of federal tax benefit	(3.00%)	(3.00%)
Valuation allowance	37.00%	37.00%
Effective tax rate

INCOME TAXES (Details Textuals)

INCOME TAXES (Details Textuals)	12 Months Ended
	Dec. 31, 2015USD ($)
Income Tax Disclosure [Abstract]
Increase in the valuation allowance	$ 529,978
Net operating loss carry-forwards	$ 23,600,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Detail Textuals) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Apr. 16, 2015	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Commitments And Contingencies [Line Items]
Base rent per month			$ 600
Settlement Expense			$ 17,693
Accounts payable				$ 239,910
Decrease in accounts payables		$ 121,504
Containing Consent Order | Federal Trade Commission (FTC)
Commitments And Contingencies [Line Items]
Settlement Expense	$ 17,693

STOCK COMPENSATION AND EQUITY39

STOCK COMPENSATION AND EQUITY BASED PAYMENTS (Details) - Warrants and Options - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Number of Warrants and Options Issued
Outstanding beginning of year	19,390,000	13,500,000
Granted	27,360,000	6,640,000
Exercised
Forfeited
Expired un-exercised		(750,000)
Outstanding end of the year	46,750,000	19,390,000
Exercisable December 31	39,916,668	13,723,335
Weighted Average Exercise Price
Outstanding beginning of year	$ 0.034	$ 0.05
Granted	$ 0.03	$ 0.03
Exercised
Forfeited
Expired un-exercised		$ 0.08
Outstanding end of the year	$ 0.032	0.034
Exercisable December 31	$ 0.032	$ 0.034

STOCK COMPENSATION AND EQUITY40

STOCK COMPENSATION AND EQUITY BASED PAYMENTS (Details 1) - Stock Options and Warrants	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Outstanding	46,750,000
Number Exercisable	39,916,668
$ 0.027
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Prices | $ / shares	$ 0.027
Number Outstanding	3,000,000
Weighted-Average Remaining Contractual Life (years)	7 years 6 months
Number Exercisable	2,000,000
Weighted Average Remaining Contractual Life (years) of Exercisable Warrants and Options	7 years 6 months
$ 0.030
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Prices | $ / shares	$ 0.030
Number Outstanding	34,000,000
Weighted-Average Remaining Contractual Life (years)	8 years 6 months
Number Exercisable	34,000,000
Weighted Average Remaining Contractual Life (years) of Exercisable Warrants and Options	8 years 6 months
$ 0.036
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Prices | $ / shares	$ 0.036
Number Outstanding	7,750,000
Weighted-Average Remaining Contractual Life (years)	7 years 9 months
Number Exercisable	5,875,000
Weighted Average Remaining Contractual Life (years) of Exercisable Warrants and Options	7 years 9 months
$ 0.040
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Prices | $ / shares	$ 0.040
Number Outstanding	1,000,000
Weighted-Average Remaining Contractual Life (years)	2 years
Number Exercisable	1,000,000
Weighted Average Remaining Contractual Life (years) of Exercisable Warrants and Options	2 years
$ 0.050
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Prices | $ / shares	$ 0.050
Number Outstanding	1,000,000
Weighted-Average Remaining Contractual Life (years)	2 years
Number Exercisable	1,000,000
Weighted Average Remaining Contractual Life (years) of Exercisable Warrants and Options	2 years

STOCK COMPENSATION AND EQUITY41

STOCK COMPENSATION AND EQUITY BASED PAYMENTS (Details 2) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
Director and consultant option expenses	$ 52,933	$ 58,416
Employee option expenses	15,350	15,350
Total stock compensation expenses	$ 68,283	$ 73,766

STOCK COMPENSATION AND EQUITY42

STOCK COMPENSATION AND EQUITY BASED PAYMENTS (Detail Textuals) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 68,283	$ 73,766
Stock Options and Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation unrecognized for stock options and warrants	$ 51,892
Average remaining vesting period for recognition of unrecognized expenses related to stock options and warrants	9 months
Weighted average remaining life of outstanding warrants and options	7 years 6 months
Aggregate intrinsic value of outstanding and exercisable options and warrants outstanding and exercisable	$ 6,000
Closing price of outstanding and exercisable options and warrants less exercise prices	0.03
Stock-based compensation	68,283	73,766
Director option expenses	33,198	33,199
Stock option expenses related to employees and consultants	$ 35,085	$ 40,567

STOCK COMPENSATION AND EQUITY43

STOCK COMPENSATION AND EQUITY BASED PAYMENTS (Detail Textuals 1) - Stock Options - USD ($)	1 Months Ended
	Oct. 21, 2013	Jul. 25, 2013
Henry Kaplan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option granted		1,500,000
Kevin Kowbel
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option granted		1,500,000
Eric Winger
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option granted		1,500,000
Messrs Kaplan And Winger
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option vest or to be vested		250,000
Exercise price of each option granted (in dollars per share)		$ 0.027
Method used for fair value assumptions		Black-Scholes pricing model
Fair value of each stock option (in dollars per share)		$ 0.020
Dividend yield		0.00%
Risk free interest rate		1.91%
Expected life of option		5 years
Expected volatility rate		98.00%
Aggregate value of stock options		$ 60,124
Vesting period of option		3 years
William F Quirk
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option granted	1,500,000
Number of option vest or to be vested	250,000
Exercise price of each option granted (in dollars per share)	$ 0.036
Expected life of option	3 years
Vesting period of option	6 months
Non cash charge for fair value of options	$ 39,471

STOCK COMPENSATION AND EQUITY44

STOCK COMPENSATION AND EQUITY BASED PAYMENTS (Detail Textuals 2) - Stock Options	1 Months Ended
	Oct. 21, 2013USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options compensation cost not yet recognized | $	$ 203,931
Options compensation cost recognition period	3 years
Employees And Consultants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option granted to purchase common stock	6,000,000
Vesting period of option	3 years
Exercise price of option | $ / shares	$ 0.036
Expiry date of option	Oct. 21, 2023
Mark A. Moore
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option granted to purchase common stock	1,000,000
Hong Zhang
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option granted to purchase common stock	750,000

STOCKHOLDERS' EQUITY (Detail Te

STOCKHOLDERS' EQUITY (Detail Textuals) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2009
Class of Stock [Line Items]
Value of stock issued, net of associated expenses		$ 568,000	$ 172,000
Dividend accrued on Series B preferred stock		206,637	373,346
Series B Preferred Stock
Class of Stock [Line Items]
Number of preferred stock issued (in shares)				19,402,675
Value of stock issued, net of associated expenses				$ 1,490,015
Dividend accrued on Series B preferred stock			$ 373,346
Accrued dividend on common stock		0.05
Dividend paid	$ 166,709
Dividend paid with issuance of common stock	3,334,179
Series B Preferred Stock | Current liability
Class of Stock [Line Items]
Dividend accrued on Series B preferred stock		$ 206,637

STOCKHOLDERS' EQUITY (Detail 46

STOCKHOLDERS' EQUITY (Detail Textuals 1)	3 Months Ended	12 Months Ended
	Sep. 30, 2015USD ($)shares	Dec. 31, 2015USD ($)$ / shares$ / Warrantshares	Dec. 31, 2014USD ($)shares
Class Of Stock [Line Items]
Proceeds from Series C Preferred Stock Issuance | $		$ 568,000	$ 172,000
Stock Options and Warrants
Class Of Stock [Line Items]
Aggregate intrinsic value of outstanding and exercisable options and warrants outstanding and exercisable | $		6,000
Closing price of outstanding and exercisable options and warrants less exercise prices | $		$ 0.03
Private placement
Class Of Stock [Line Items]
Shares warrant feature per share (in dollars per share)		$ 0.03
Shares contingency warrant feature per share (in dollars per share)		$ 0.06
Stock, contingency warrant exercise description		The contingency warrants will be issued only if the Company has not attained profitability by the end of the first quarter 2016. The holders must exercise fifty percent of the warrants if the market price for the Company's common stock is $0.20 for a period of thirty consecutive calendar days.
Percentage of warrants exercise if market price for company's common stock is $0.20		50.00%
Price per share for exercise of warrants, condition one		$ 0.20
Number of days for common stock price at $0.20		30 days
Percentage of warrants exercise if market price for company's common stock is $0.30		50.00%
Price per share for exercise of warrants, condition two | $ / Warrant		0.30
Number of days for common stock price at $0.30		30 days
Fair value of exercise price of warrants		$ 0.022
Valuation method for warrants		Black Scholes Method
Number of shares authorized for issuance | shares	7,000,000
Stock issued under private placement | shares		4,000,000
Proceeds from private placement of common stock | $		$ 120,000
Series C Preferred Stock
Class Of Stock [Line Items]
Proceeds from Series C Preferred Stock Issuance | $	$ 560,732
Shares warrant feature per share (in dollars per share)		$ 0.03
Shares contingency warrant feature per share (in dollars per share)		$ 0.03
Stock, contingency warrant exercise description		The contingency warrants will be issued only if the Company has not attained profitability by the end of the first quarter 2016. The holders must exercise fifty percent of the warrants if the market price for the Company's common stock is $0.20 for a period of thirty consecutive calendar days.
Percentage of warrants exercise if market price for company's common stock is $0.20		50.00%
Price per share for exercise of warrants, condition one		$ 0.20
Number of days for common stock price at $0.20		30 days
Percentage of warrants exercise if market price for company's common stock is $0.30		50.00%
Price per share for exercise of warrants, condition two | $ / Warrant		0.30
Number of days for common stock price at $0.30		30 days
Fair value of exercise price of warrants		$ 0.022
Valuation method for warrants		Black Scholes Method
Stock issued under private placement | shares		30,000,000	6,640,000

INVESTMENT IN AVAILABLE FOR S47

INVESTMENT IN AVAILABLE FOR SALE SECURITIES (Detail Textuals) - USD ($)	1 Months Ended	12 Months Ended
	Jan. 31, 2012	Dec. 31, 2015	Dec. 31, 2014
Schedule of Available-for-sale Securities [Line Items]
Number of shares sold during third and fourth quarters of 2012		268,718,989	261,384,810
Amount of shares sold during third and fourth quarters of 2012		$ 120,000
Neo Genomics Laboratories Inc
Schedule of Available-for-sale Securities [Line Items]
Unrecognized loss on available for sale securities		$ 123,161
Number of remaining shares held		18,000
Number of shares sold during third and fourth quarters of 2012		68,900
Amount of shares sold during third and fourth quarters of 2012		$ 331,465
Realized gain on sale of available for sale securities		$ 232,937
Number of shares of Neo Genomics stock held		18,000	86,900
Number of shares initially acquired	1,360,000
Carrying value | Neo Genomics Laboratories Inc
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities		$ 1,945,000
Fair value | Neo Genomics Laboratories Inc
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities		$ 141,978

SUBSEQUENT EVENTS (Detail Textu

SUBSEQUENT EVENTS (Detail Textuals) - Stock Options - USD ($)	Feb. 08, 2016	Oct. 21, 2013
Subsequent Event [Line Items]
Options compensation cost not yet recognized		$ 203,931
Options compensation cost recognition period		3 years
Employees And Consultants
Subsequent Event [Line Items]
Number of option granted to purchase common stock		6,000,000
Vesting period of option		3 years
Exercise price of option		$ 0.036
Expiry date of option		Oct. 21, 2023
Mark A. Moore
Subsequent Event [Line Items]
Number of option granted to purchase common stock		1,000,000
Hong Zhang
Subsequent Event [Line Items]
Number of option granted to purchase common stock		750,000
Subsequent Event
Subsequent Event [Line Items]
Options compensation cost not yet recognized	$ 109,721
Options compensation cost recognition period	2 years
Subsequent Event | Employees And Consultants
Subsequent Event [Line Items]
Number of option granted to purchase common stock	5,000,000
Vesting period of option	2 years
Exercise price of option	$ 0.03
Expiry date of option	Feb. 8, 2026
Subsequent Event | Mark A. Moore
Subsequent Event [Line Items]
Number of option granted to purchase common stock	500,000
Subsequent Event | Hong Zhang
Subsequent Event [Line Items]
Number of option granted to purchase common stock	1,250,000

FINANCIAL CONDITION AND GOING49

FINANCIAL CONDITION AND GOING CONCERN (Detail Textuals) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Financial Condition and Going Concern [Abstract]
Cash	$ 417,208	$ 7,642	$ 71,991
Investment in NeoGenomics Stock available for sale	141,978	362,373
Series C Preferred stock offering	568,000	$ 172,000
Additional preferred stock offering received	332,000
Net issuance of preferred stock	$ 900,000